

Phone: +91 9959390412 Fax: +91-40-24220320 Website: www.geethanjaliinstitutions.com

# Geethanjali College of Pharmacy

Approved by AICTE, PCI New Delhi, Permanently Affiliated to JNTUH & B. Pharmacy Accredited by NBA Recognized Under UGC Section 2F & 12B of UGC Act, 1956, by DSIR-SIRO & HI/BI of MSME, Certified by ISO 9001:2015

Cheeryal (V), Keesara (M), Medchal-Malkajgiri Dist, Telangana State- 501301.

### PROGRAM: DOCTOR OF PHARMACY (POST BACCALAUREATE)

### **BATCH (18-21)** AY (2020-2021) REGULATION R08

#### Course **CO** Statement Code Course Knowledge Relevance Name Outcome Level to PO's No PROGRAM: DOCTOR OF PHARMACY(PB) I/III PHARMA PD.C4 PD.C.41. Describe the pathophysiology of selected K3 PO1 1 1 CO disease states and PO2 the rationale for drug therapy PO3 THERAPE UTICS-III PD.C.41. Discover the therapeutic K4 PO4 2 approach to manage diseases PO5 Appreciate the controversies in PO6 PD.C.41. K4 3 PO7 drug therapy Analyze the importance of preparation of PO8 PD.C.41. K4 4 PO9 individualized therapeutic plans based on PO1 0

## COURSE OUTCOMES WITH KNOWLEDGE LEVEL & ITSRELEVANCE TO PROGRAM OUTCOMES

			Diagnosis		PO11
		PD.C.41.5	Choose the latest available	K3	
			evidence to manage diseases		
		PD.C.41.6	Identify the patient-specific	K3	
			parameters relevant in initiating		
			drug therapy, and monitoring		
			therapy		
HOSPITAL	PD.C42	PD.C.42.1	Use professional practice	K3	PO1
PHARMACY			management skills in hospital		PO2
			pharmacies		PO3
		PD.C.42.2	Recommend unbiased drug	K5	PO4
			information to the doctors		PO5
		PD.C.42.3	Develop the manufacturing	K3	PO6
			practices of various formulations		PO7
			in hospital set up		PO8
					PO9
		PD.C.42.4	Select the practice based	K4	PO10
		DD C 42.5	research methods	V A	POIT
		FD.C.42.3	and inventory control skills	<b>N</b> 4	
CLINICAL	PD.C43	PD.C.43.1	Monitor drug therapy of patient	K4	
PHARMACY			through medication chart		
			review and clinical review		
		PD.C.43.2	Analyse medication history	K4	PO1
			interview and counsel the		PO2
			patients		PO4
		PD C 43.3	Determine and resolve drug	K6	- PO6
		12.01.00	related problems		PO/
			related proceeding		PO8
		PD.C.43.4	Determine, assess and	K4	PO9
			investigate adverse drug		PO10 PO11
			reaction		FOIL
		PD.C.43.5	Interpret selected laboratory	K6	
			results (as monitoring		
			parameters in the peutics) of specific disease states		
		PD C 43.6	Adapt analyse interpret and	К5	-
		10.0.73.0	formulate drug or medicine	115	

			information		
BIOSTATIST ICS &RESEARC H METHODOL	PD.C44	PD.C44.1	Choose the appropriate research design and develop research hypothesis for a research project.	К3	
OGY		PD.C44.2	Discuss the various steps involved in conducting research and describe the sample size calculation methods.	К3	PO3 PO4
		PD.C44.3	Construct a frequency table, histogram, pie chart to represent a data set	K3	PO9 PO11
		PD.C44.4	Identify the fundamentals of the most parametric and non parametric techniques for statistical inference	К3	
		PD.C44.5	Compute and interpret the Spearman correlation coefficient and test the significance	К3	
		PD.C44.6	Operate various softwares for statistical analysis of data and appreciate the importance of Computers in hospital and Community Pharmacy	К3	
BIOPHARM ACEUTICS & PHARMACO KINETICS	PD.C45	PD.C.45.1	Discuss and broader understanding about the concepts of biopharmaceutics and pharmacokinetics.	K4	PO1
		PD.C.45.2	Select the correct pharmacokinetic model basedon plasma level or urinary excretion data that best describes the process of drug absorption, distribution, metabolism and elimination(ADME)	K6	PO3 PO4 PO5 PO6 PO7 PO8 PO9 PO10

					PO11
		PD.C.45.3	Ability to calculate the various pharmacokinetic parameters by using various mathematical models.	K5	
		PD.C.45.4	Carry out biopharmaceutical studies and use data so obtained in the development of new drugs or dosage forms	K4	-
		PD.C.45.5	Calculate various pharmacokinetic parameters from plasma and urinary excretion data applying compartment modeling and model independent methods	K4	
		PD.C.45.6	Design dosage regimens for patients based on calculated pharmacokinetic parameters	K4	-
		PD.C.45.7	Design Bioavailability and Bioequivalence studies of new drugs or dosage form	K6	
		PD.C.45.8	Evaluate drug-protein bindingas a tool to predict pharmacokinetics of drugs	K5	
CLINICAL TOXICOLOG Y	PD.C46	PD.C.46.1	Illustrate general principles and management practice of poisoning	K3	PO1 PO3 PO4
		PD.C.46.2	Differentiate the history, assessment, and therapy considerations associated withthe management of a toxic exposure	K4	PO6 PO7 PO9 PO10 PO11
		PD.C.46.3	Demonstrating and understanding of the characteristics of and treatment	K3	1

			guidelines for specific toxic		
			substances		
		PD.C.46.4	Relationship of the pharmacistto	K4	]
			function as contributing health		
			care team in poison management		
		PD.C.46.5	Comparing symptoms and	K2	]
			management of various types of		
			toxic exposures		
			1		
		PD.C.46.6	Proposing several preventive	K5	
			approaches to reduce		
			unintentional drug, plant and		
			animal poisonings		
PHARMACO	PD.C47	PD.C.47.1	Explain the rationale for drug	K5	PO1
THERAPEUT			therapy		PO2
ICS-III LAB		PD.C.47.2	Apply the therapeutic approachto	K3	PO3
			management of diseases including		PO4
			reference to the latest		PO5
			available evidence		PO6
		PD.C.47.3	Identify the controversies in	К3	PO7
			drug therapy		PO8
		PD.C.47.4	Recommend individualized	K5	PO9
			therapeutic plans based on		PO10
			diagnosis		PO11
		PD.C.47.5	Identify the patient-specific	К3	-
			parameters relevant in initiating		
			drug therapy and monitoring		
			therapy (including alternatives		
			time course of clinical and		
			laboratory indices of therepoutie		
			laboratory indices of therapeutic		
			response and		
			adverse effects)		
HOSPITAL	PD.C48	<b>PD.C.48</b> .1	Analyze prescriptions for drug	<b>K</b> 4	PO1
PHARMACY			interactions		PO2
LAB		<b>PD.C.48</b> .2	Illustrate, Formulate and prepare	K3	PO3
			parenteral formulations		PO4
			and powders		PO5
		<b>PD.C.48</b> .3	Perform inventory analysis	К3	PO6
					PO7
		PD.C.48.4	Analyze and Answer drug	K4	PO8
			information queries through		

			literature search		PO9
		<b>PD.C.48</b> .5	Conduct planned experiments and	K5	PO10
			prepare laboratory report in		PO11
			a standard format		
CLINICAL	PD.C49	<b>PD.C.49</b> .1	Discuss Drug information	K4	PO1
PHARMACY			questions and answering		PO2
LAB				T/C	PO3
		<b>PD.C.49</b> .2	Discuss effective Patient	K6	PO4
			medication counselling		PO5
		<b>PD.C.49</b> .3	Discuss case studies related to	К5	PO6
		12101110	laboratory investigations and		PO7
			examine laboratory values		PO8
					PO9
		<b>PD.C.49</b> .4	Discuss Patient medication	K4	PO10
			history interview		PO11
		DD C 40 5	Pind dama dama internationalia	V A	_
		FD.C.49.5	Find drug drug interactions in	Λ4	
			case studies		
BIOPHARM	PD.C41	PD.C410.1	Compare the invitro drug	K4	
ACEUTICS &	0		release profile of different		
PHARMACO			marketed products		
KINETICS			-		_
LAB		PD.C.410.	Perform the solubility	K4	
		2	enhancement techniques for		
			improvement of drug release of		PO1
			poorly water soluble drug		PO2
		PD C 410	Estimate the bioavailability	K6	PO3
		3	(absolute and relative) and	110	PO4
		_	bioequivalence from the given		PO5
			clinical data		PO6
					PO7
		PD.C.410.	Calculate the drug content in	K4	PO8
		4	blood sample using Area Under		PO9
			Curve approach		PO10
		DD C 410		VC	PO11
		PD.C.410.	Calculate and interpret various	KO	
		3	pharmacokinetic parameters from		
			the given chinical data		
		PD.C.410.	Conduct planned experiments and	K5	-
		6	prepare laboratory report ina		
			standard format		
	DOCTO	OR OF PHAR	MACY (POST BACCALAUREATE	C) II/III	

CLINICAL	PD.C51	PD.C51.1	Outline the new drug	K2	PO1
RESEARCH			development process as per		PO2
			regulatory and ethical		PO3
			requirements		PO4
		PD.C51.2	Explain the roles and	K2	PO5
			responsibilities of various		PO6
			personnel involved in clinical		PO7
			trials as per ICH-GCP		PO8
		PD.C51.3	Demonstrate competencies in	K3	PO9
			evaluating clinical research		PO10
			data and communicating results		PO11
		PD.C51.4	List out various clinical trial	K4	
			activity & its documentation asper		
			regulatory and ethical		
			requirements		
		PD.C51.5	Distinguish about various	K4	
			regulatory submissions & its		
			environment in India, USA &		
			Europe		
PHARMACO	PD.C52	PD.C52.1	Explain about definition and	K6	
EPIDEMIOL			scope of		
OGY AND			pharmacoepidemiology and		
PHARMACO			discuss measurement of		
ECONOMICS			outcomes in		
			pharmacoepidemiology.		PO1
		PD.C52.2	Measure concept of risk in	K6	PO2
			pharmacoepidemiology		PO3
		PD.C52.3	Classify various methods of	K4	PO4
			pharmacoepidemiology and		PO5
			Classify sources of data for		PO6
			pharmacoepidemiological		PO7
			studies		PO8
		PD.C52.4	Explain about selected special	K6	PO9
			applications of		PO10
			pharmacoepidemiology		PO11
		PD.C52.5	Explain about role in formulary	K6	-
			management decision		
		PD.C52.6	Explain the methods used in	K6	-
			pharmacoeconomic analysis and		
			Discuss about applications		
			of pharmacoeconomics		
CLINICAL	PD.C53	PD.C.53.1	Describing Pharmacokinetic	K4	1
PHARMACO			principles in drug monitoring		

KINETICS &	PD.C.53.2	Demonstrating the Conversion	K3	
PHARMACO		of dosage forms		
THERAPEUT	PD.C.53.3	Interpretation of	K3	
IC DRUG		Pharmacokinetic drug		
MONITORIN		interactions		
G	PD.C.53.4	Make up the individualization of	K5	PO1
		dosage regimen as per		PO2
		demographic parameters		PO3
	PD.C.53.5	Prioritize the dosage	K4	PO4
		adjustments in Renal and		PO6
		Hepatic diseases		PO7
	PD.C.53.6	Assess the use of	K6	PO9
		pharmacogenetics in Pk and		PO10
		pharmacodynamic principles		PO11

Sponsored by TEJA EDUCATIONAL SOCIETY, HYDERABAD Office : Sy. No: 33 & 34, Cheeryal (V), Keesara (M), Medchal-Malkajgiri Dist, Telangana State- 501301. Mobile : 9866308259